{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:01:03Z","timestamp":1761541263631},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Programme","award":["FP7\/2013-2016"],"award-info":[{"award-number":["FP7\/2013-2016"]}]}],"content-domain":{"domain":["thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.radonc.2015.05.015","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T08:42:02Z","timestamp":1434444122000},"page":"308-313","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Re-distribution of brachytherapy dose using a differential dose prescription adapted to risk of local failure in low-risk prostate cancer patients"],"prefix":"10.1016","volume":"115","author":[{"given":"Susanne","family":"Rylander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Polders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel J.","family":"Steggerda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc M.","family":"Moonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Tanderup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uulke A.","family":"Van der Heide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2015.05.015_b0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.urology.2008.07.064","article-title":"Population-based study of biochemical and survival outcomes after permanent 125-I brachytherapy for low- and intermediate-risk prostate cancer","volume":"73","author":"Morris","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2015.05.015_b0010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brachy.2011.05.011","article-title":"Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy","volume":"11","author":"Lubbe","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2015.05.015_b0020","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.brachy.2011.08.003","article-title":"Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: the Memorial Sloan-Kettering cancer center experience","volume":"11","author":"Zelefsky","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2015.05.015_b0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2006.08.056","article-title":"Multi-institutional analysis of long-term outcome for stages T1\u2013T2 prostate cancer, treated with permanent seed implantation","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.radonc.2013.07.019","article-title":"Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?","volume":"109","author":"Steggerda","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ijrobp.2008.11.043","article-title":"Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up","volume":"75","author":"Keyes","year":"2009","journal-title":"Int J Radiat Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0040","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.ijrobp.2009.06.083","article-title":"The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life","volume":"77","author":"Roeloffzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ijrobp.2010.06.009","article-title":"Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy","volume":"81","author":"Roeloffzen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0050","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.juro.2007.08.072","article-title":"Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities","volume":"178","author":"Eggener","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2015.05.015_b0055","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/j.1464-410X.2011.10633.x","article-title":"Transatlantic consensus group on active surveillance and focal therapy for prostate cancer","volume":"109","author":"Ahmed","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2015.05.015_b0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2011.10825.x","article-title":"Report of consensus meeting on focal low-dose-rate brachytherapy for prostate cancer","volume":"109","author":"Langley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2015.05.015_b0065","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.juro.2012.06.010","article-title":"Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy","volume":"188","author":"Nguyen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2015.05.015_b0070","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.brachy.2014.06.007","article-title":"Dosimetry modeling for focal high-dose-rate prostate brachytherapy","volume":"13","author":"Mason","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2015.05.015_b0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2015.05.015_b0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/0284186X.2012.744875","article-title":"Improved tumour control probability with MRI-based prostate brachytherapy treatment planning","volume":"52","author":"Dinkla","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0085","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3109\/0284186X.2013.787164","article-title":"Why prostate tumour delineation based apparent diffusion coefficient is challenging: an exploration of the tissue microanatomy","volume":"52","author":"Borren","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0090","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1148\/radiol.2493080236","article-title":"Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers","volume":"249","author":"Langer","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2015.05.015_b0095","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.juro.2011.07.013","article-title":"Multiparametric 3T prostate magnetic resonance to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based models","volume":"186","author":"Turkbey","year":"2011","journal-title":"Jour Urol"},{"key":"10.1016\/j.radonc.2015.05.015_b0100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-014-1557-y","article-title":"Re-evaluating the concept of \u201cdominant\/index tumor nodule\u201d in multifocal prostate cancer","volume":"464","author":"Huang","year":"2014","journal-title":"Virshows Arch"},{"key":"10.1016\/j.radonc.2015.05.015_b0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","article-title":"Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0110","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijrobp.2010.10.060","article-title":"Moving toward focal therapy in prostate cancer: dual-isotope permanent seeds implants as a possible solution","volume":"81","author":"Todor","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0115","first-page":"1","article-title":"Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer","volume":"16","author":"Polders","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","article-title":"Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy","volume":"83","author":"Salembier","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.meddos.2003.04.001","article-title":"Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (bed) vs. conventional dose","volume":"28","author":"Singh","year":"2003","journal-title":"Med Dosim"},{"key":"10.1016\/j.radonc.2015.05.015_b0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ijrobp.2008.11.039","article-title":"Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling","volume":"73","author":"Fowler","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0135","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1259\/bjr.71.845.9691890","article-title":"The clinical radiobiology of brachytherapy","volume":"71","author":"Dale","year":"1998","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2015.05.015_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the \u03b1\/\u03b2 ratio for prostate cancer?","volume":"55","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0360-3016(02)02755-4","article-title":"Biological effective dose for permanent prostate brachytherapy taking into account post implant edema","volume":"53","author":"Van Gellekom","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0150","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0360-3016(87)90352-X","article-title":"Radiation repair in human endothelial cells","volume":"13","author":"Marchese","year":"1987","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0155","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1118\/1.4712224","article-title":"What do we know about \u03b1\/\u03b2 for prostate cancer?","volume":"39","author":"Oliveira","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0160","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0360-3016(03)01455-X","article-title":"How low is the \u03b1\/\u03b2 ratio for prostate cancer","volume":"57","author":"Kal","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","article-title":"Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology","volume":"78","author":"P\u00f6tter","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.radonc.2014.04.016","article-title":"Multi-modality functional image guided dose escalation in the presence of uncertainties","volume":"111","author":"Alber","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.brachy.2009.07.010","article-title":"Minimizing the number of implantation needles for prostate 125I brachytherapy: an investigation of possibilities and implications","volume":"9","author":"Steggerda","year":"2010","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2015.05.015_b0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.radonc.2009.12.012","article-title":"Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy","volume":"94","author":"Polo","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2015.05.015_b0185","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2015.05.015_b0190","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1464-410X.2007.07083.x","article-title":"Evaluation of [11C]-choline positron-emission\/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment of prostate cancer","volume":"100","author":"Rinnab","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2015.05.015_b0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","article-title":"Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of the primary tumor: magnetic resonance imaging and step-section pathology evidence","volume":"69","author":"Pucar","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814015002650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:24:57Z","timestamp":1537543497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814015002650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0167814015002650"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2015.05.015","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-distribution of brachytherapy dose using a differential dose prescription adapted to risk of local failure in low-risk prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2015.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}